首页> 外文期刊>Journal of Surgical Research: Clinical and Laboratory Investigation >Combined intrathymic and intravenous injection of mesenchymal stem cells can prolong the survival of rat cardiac allograft associated with decrease in miR-155 expression
【24h】

Combined intrathymic and intravenous injection of mesenchymal stem cells can prolong the survival of rat cardiac allograft associated with decrease in miR-155 expression

机译:胸腺内和静脉内注射间充质干细胞可延长大鼠心脏同种异体移植的存活,并降低miR-155的表达

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Mesenchymal stem cells (MSCs) have the potential to improve graft outcomes and promote allograft tolerance. In this study, we examined the effects and mechanism of combined intrathymic (IT) and intravenous (IV) injection of MSCs on the survival of transplanted hearts in a rat allograft model. Methods: Recipient Sprague-Dawley rats were transplanted with hearts from Wistar rats. Wistar rat MSCs were infused via IT or IV or combined IT and IV (IT/IV) injection at designated intervals. In vitro mixed lymphocyte reaction assays were performed to assess the immunosuppressive capacity of MSCs. Mesenchymal stem cell surface markers and CD4, CD25, and Foxp3 T-cells in the peripheral blood were detected using flow cytometry analysis. The expression of microRNAs and cytokines in graft infiltrating lymphocytes was analyzed by real-time polymerase chain reaction. Results: The MSCs cultured in vitro had multipotential differentiation capacity. Mixed lymphocyte reaction assays showed that donor-derived MSCs could not stimulate a proliferative response of recipient lymphocytes and could markedly suppress T-cell responses. Survival of the allografts was significantly prolonged by administration of IT/IV injection of MSCs compared with controls, with a mean survival of 32.2 versus 6.5 d, respectively. Compared with the syngeneic groups posttransplant, miR-155 expression was significantly increased in the allogeneic group, and could be restored by injection of MSCs, especially IT/IV injection of MSCs. Moreover, IT/IV injection of MSCs decreased the level of interleukin (IL)-2 and interferon-gamma, but increased the levels of IL-4 and IL-10 in the allogeneic group. More important, IT/IV injection of MSCs was the best way to increase the percentage of CD4, CD25, and Foxp3 T-cell peripheral blood. Conclusions: Our results indicated that IT/IV injection of MSCs can prolong the survival of rat cardiac allograft, which may be associated with down-regulating miR-155 expression, a shift in the Th1/Th2 balance, and up-regulation of Treg cells expression.
机译:背景:间充质干细胞(MSCs)具有改善移植效果和促进同种异体移植耐受性的潜力。在这项研究中,我们研究了在大鼠同种异体移植模型中胸腺内(IT)和静脉内(IV)联合注射MSC对移植心脏存活的影响和机制。方法:将接受Sprague-Dawley的大鼠移植至Wistar大鼠的心脏。以指定的时间间隔通过IT或IV或联合IT和IV(IT / IV)注射来注入Wistar大鼠MSC。进行体外混合淋巴细胞反应测定以评估MSC的免疫抑制能力。使用流式细胞仪分析检测外周血中的间充质干细胞表面标志物和CD4,CD25和Foxp3 T细胞。通过实时聚合酶链反应分析microRNAs和细胞因子在移植的浸润淋巴细胞中的表达。结果:体外培养的MSC具有多能分化能力。混合淋巴细胞反应测定表明,供体来源的MSC不能刺激受体淋巴细胞的增殖反应,并且可以显着抑制T细胞反应。与对照组相比,IT / IV注射MSCs显着延长了同种异体移植的存活时间,平均存活率分别为32.2和6.5 d。与移植后的同基因组相比,同种异体组的miR-155表达显着增加,并且可以通过注射MSCs,尤其是IT / IV注射MSCs恢复。此外,IT / IV注射MSC可以降低同种异体组的白介素(IL)-2和干扰素-γ的水平,但可以提高IL-4和IL-10的水平。更重要的是,IT / IV注射MSC是增加CD4,CD25和Foxp3 T细胞外周血百分比的最佳方法。结论:我们的结果表明,IT / IV注射MSCs可以延长大鼠心脏同种异体移植的存活,这可能与下调miR-155表达,改变Th1 / Th2平衡以及上调Treg细胞有关表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号